Evercore ISI lowered the firm’s price target on Quest Diagnostics (DGX) to $210 from $220 and keeps an In Line rating on the shares as the firm made several price target adjustments and additions to the firm’s Tactical call lists as part of the firm’s healthcare technology and distribution preview for Q1. Among the changes, the firm added Quest Diagnostics to its “Tactical Outperform” list.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- The Week That Was, The Week Ahead: Macro and Markets, April 5
- Quest Diagnostics Adds Veteran Healthcare Leader to Board
- Quest Diagnostics elects Timothy Wentworth to Board of Directors
- Quest Diagnostics names Benjamin Beauvalot VP, Chief Strategy and M&A Officer
- Labcorp guidance ‘should be well received,’ says Morgan Stanley